Published in Acta Biochim Biophys Sin (Shanghai) on September 15, 2015
ISL1, a novel regulator of CCNB1, CCNB2 and c-MYC genes, promotes gastric cancer cell proliferation and tumor growth. Oncotarget (2016) 0.78
GLI1-mediated regulation of side population is responsible for drug resistance in gastric cancer. Oncotarget (2017) 0.75
YAP signaling in gastric cancer-derived mesenchymal stem cells is critical for its promoting role in cancer progression. Int J Oncol (2017) 0.75
The role of GLI2-ABCG2 signaling axis for 5Fu resistance in gastric cancer. J Genet Genomics (2017) 0.75
Global cancer statistics, 2012. CA Cancer J Clin (2015) 53.52
Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer (2014) 40.30
Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med (2001) 24.51
THE TWO HISTOLOGICAL MAIN TYPES OF GASTRIC CARCINOMA: DIFFUSE AND SO-CALLED INTESTINAL-TYPE CARCINOMA. AN ATTEMPT AT A HISTO-CLINICAL CLASSIFICATION. Acta Pathol Microbiol Scand (1965) 22.65
Tumour stem cells and drug resistance. Nat Rev Cancer (2005) 15.21
Comprehensive molecular characterization of gastric adenocarcinoma. Nature (2014) 11.93
Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med (2001) 11.88
5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer (2003) 11.78
Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene (2003) 10.74
EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene (2010) 9.66
Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol (2006) 9.16
Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med (2014) 6.95
Fluorinated pyrimidines, a new class of tumour-inhibitory compounds. Nature (1957) 6.34
PI3K/Akt signalling pathway and cancer. Cancer Treat Rev (2004) 5.46
Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology (2008) 5.31
Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study. Lancet Oncol (2009) 5.19
Targeting DNA topoisomerase II in cancer chemotherapy. Nat Rev Cancer (2009) 5.06
Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res (1997) 4.34
Patient-derived models of acquired resistance can identify effective drug combinations for cancer. Science (2014) 4.34
Environment-mediated drug resistance: a major contributor to minimal residual disease. Nat Rev Cancer (2009) 3.49
Gastric cancer, version 2.2013: featured updates to the NCCN Guidelines. J Natl Compr Canc Netw (2013) 3.03
Activation of the PI3K/Akt pathway and chemotherapeutic resistance. Drug Resist Updat (2002) 2.95
Identification of molecular subtypes of gastric cancer with different responses to PI3-kinase inhibitors and 5-fluorouracil. Gastroenterology (2013) 2.46
Cisplatin as an anti-tumor drug: cellular mechanisms of activity, drug resistance and induced side effects. Cancers (Basel) (2011) 2.31
XIAP regulates Akt activity and caspase-3-dependent cleavage during cisplatin-induced apoptosis in human ovarian epithelial cancer cells. Cancer Res (2001) 2.25
Treatment of gastric cancer. World J Gastroenterol (2014) 1.93
The tumor microenvironment is a dominant force in multidrug resistance. Drug Resist Updat (2012) 1.77
Phosphoinositide 3-kinase/Akt pathway plays an important role in chemoresistance of gastric cancer cells against etoposide and doxorubicin induced cell death. Int J Cancer (2008) 1.64
FGF receptors: cancer biology and therapeutics. Med Res Rev (2013) 1.59
Genetics of gastric cancer. Nat Rev Gastroenterol Hepatol (2014) 1.56
The emerging role of MET/HGF inhibitors in oncology. Cancer Treat Rev (2013) 1.54
The modulation of ABC transporter-mediated multidrug resistance in cancer: a review of the past decade. Drug Resist Updat (2014) 1.54
Effect of extracellular signal-regulated kinase on p53 accumulation in response to cisplatin. J Biol Chem (2000) 1.53
Gastric cancer: Classification, histology and application of molecular pathology. J Gastrointest Oncol (2012) 1.53
FGFR2 gene amplification in gastric cancer predicts sensitivity to the selective FGFR inhibitor AZD4547. Clin Cancer Res (2013) 1.51
Highly frequent PIK3CA amplification is associated with poor prognosis in gastric cancer. BMC Cancer (2012) 1.39
What a tangled web we weave: emerging resistance mechanisms to inhibition of the phosphoinositide 3-kinase pathway. Cancer Discov (2013) 1.38
Update on taxane development: new analogs and new formulations. Drug Des Devel Ther (2012) 1.36
Structure and function of the human breast cancer resistance protein (BCRP/ABCG2). Curr Drug Metab (2010) 1.33
Drug transporters in drug efficacy and toxicity. Annu Rev Pharmacol Toxicol (2011) 1.31
Sonic hedgehog pathway is essential for maintenance of cancer stem-like cells in human gastric cancer. PLoS One (2011) 1.30
Current questions for the treatment of advanced gastric cancer. Cancer Treat Rev (2012) 1.27
Mismatch repair and response to DNA-damaging antitumour therapies. Eur J Cancer (2003) 1.26
Multidrug resistance proteins (MRPs, ABCCs): importance for pathophysiology and drug therapy. Handb Exp Pharmacol (2011) 1.25
Beta1-integrin circumvents the antiproliferative effects of trastuzumab in human epidermal growth factor receptor-2-positive breast cancer. Cancer Res (2009) 1.21
HER2, MET and FGFR2 oncogenic driver alterations define distinct molecular segments for targeted therapies in gastric carcinoma. Br J Cancer (2014) 1.16
A better platinum-based anticancer drug yet to come? Anticancer Agents Med Chem (2010) 1.12
Aldehyde dehydrogenase high gastric cancer stem cells are resistant to chemotherapy. Int J Oncol (2013) 1.09
Expression of survivin mRNA and protein in gastric cancer cell line (MKN-45) during cisplatin treatment. Apoptosis (2002) 1.07
Progression-Free and Overall Survival in ALK-Positive NSCLC Patients Treated with Sequential Crizotinib and Ceritinib. Clin Cancer Res (2015) 1.07
Gastric cancer review. J Carcinog (2014) 1.06
Induction of apoptosis by cisplatin and its effect on cell cycle-related proteins and cell cycle changes in hepatoma cells. Cancer Lett (2002) 1.04
Evaluation of the 7th UICC TNM Staging System of Gastric Cancer. J Gastric Cancer (2011) 1.04
Review of capecitabine as oral treatment of gastric, gastroesophageal, and esophageal cancers. Cancer (2006) 1.01
Classification of gastric carcinoma. Hepatogastroenterology (1990) 0.99
S-1-based combination therapy vs S-1 monotherapy in advanced gastric cancer: a meta-analysis. World J Gastroenterol (2014) 0.96
CD44 expression denotes a subpopulation of gastric cancer cells in which Hedgehog signaling promotes chemotherapy resistance. Clin Cancer Res (2014) 0.95
Targeted therapy in gastric cancer. APMIS (2015) 0.91
No improvement in median survival for patients with metastatic gastric cancer despite increased use of chemotherapy. Ann Oncol (2013) 0.91
Cisplatin-resistant prostate cancer model: Differences in antioxidant system, apoptosis and cell cycle. Int J Oncol (2013) 0.91
Molecular basis for sensitivity and acquired resistance to gefitinib in HER2-overexpressing human gastric cancer cell lines derived from liver metastasis. Br J Cancer (2006) 0.88
Multimodal treatment of gastric cancer. World J Gastrointest Surg (2014) 0.87
Molecular targeted therapies in advanced gastric cancer: does tumor histology matter? Therap Adv Gastroenterol (2013) 0.87
Paclitaxel combined with capecitabine as first-line chemotherapy for advanced or recurrent gastric cancer. Oncol Lett (2014) 0.86
Role of epirubicin in advanced breast cancer. Clin Breast Cancer (2000) 0.84
Making capecitabine targeted therapy for breast cancer: which is the role of thymidine phosphorylase? Clin Breast Cancer (2012) 0.83
Docetaxel versus paclitaxel combined with 5-FU and leucovorin in advanced gastric cancer: combined analysis of two phase II trials. Cancer Res Treat (2009) 0.82
Droplet digital PCR measurement of HER2 in patients with gastric cancer. Br J Cancer (2015) 0.82
New insights into the RNA-based mechanism of action of the anticancer drug 5'-fluorouracil in eukaryotic cells. PLoS One (2013) 0.81
Ulinastatin reduces the resistance of liver cancer cells to epirubicin by inhibiting autophagy. PLoS One (2015) 0.81
Ganoderma lucidum polysaccharide exerts anti-tumor activity via MAPK pathways in HL-60 acute leukemia cells. J Recept Signal Transduct Res (2014) 0.81
Involvement of p53 in the repair of DNA double strand breaks: multifaceted Roles of p53 in homologous recombination repair (HRR) and non-homologous end joining (NHEJ). Subcell Biochem (2014) 0.80
Molecular basis of 5-fluorouracil-related toxicity: lessons from clinical practice. Anticancer Res (2014) 0.80
An epigenetic mechanism for capecitabine resistance in mesothelioma. Biochem Biophys Res Commun (2009) 0.80
MET as a potential target for the treatment of upper gastrointestinal cancers: characterization of novel c-Met inhibitors from bench to bedside. Curr Med Chem (2014) 0.79
Arsenic Inhibits DNA Mismatch Repair by Promoting EGFR Expression and PCNA Phosphorylation. J Biol Chem (2015) 0.79
The selective intravenous inhibitor of the MET tyrosine kinase SAR125844 inhibits tumor growth in MET-amplified cancer. Mol Cancer Ther (2014) 0.78
Linitis plastica: one disease or more? J Clin Gastroenterol (1982) 0.76